- Conditions
- Cervical Cancer, Fallopian Tube Cancer, Head and Neck Cancer, Lung Cancer, Malignant Mesothelioma, Ovarian Cancer, Pancreatic Cancer, Primary Peritoneal Cavity Cancer
- Interventions
- SS1(dsFv)-PE38 immunotoxin
- Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 577–600
of 2,243
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Solid Tumors
- Interventions
- INCB057643, Gemcitabine, Paclitaxel, Rucaparib, Abiraterone, Ruxolitinib, Azacitidine
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 137 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • La Jolla, California • Denver, Colorado + 12 more
- Conditions
- Cancer
- Interventions
- filgrastim, carboplatin, cisplatin, cyclophosphamide, etoposide, ifosfamide, mesna, paclitaxel, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1994 – 2015
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Colorectal Cancer
- Interventions
- fluorouracil, gemcitabine hydrochloride, leucovorin calcium
- Drug
- Lead sponsor
- Stony Brook University
- Other
- Eligibility
- Not listed
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1997
- U.S. locations
- 1
- States / cities
- Stony Brook, New York
- Conditions
- Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
- Interventions
- Pumitamig, Folfox, Capox, Nivolumab
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 690 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 34
- States / cities
- Phoenix, Arizona • Los Angeles, California • Orange, California + 29 more
- Conditions
- Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma, Localized Non-Resectable Adult Liver Carcinoma, Recurrent Adult Liver Carcinoma
- Interventions
- Akt Inhibitor MK2206, Laboratory Biomarker Analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 22
- States / cities
- Beverly Hills, California • Duarte, California • Los Angeles, California + 18 more
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- Sorafenib (Nexavar, BAY43-9006), Placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 602 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 35
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 24 more
- Conditions
- Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma Recurrent, Carcinoma, Hepatocellular, Liver Diseases, Neoplasms by Histologic Type, Digestive System Neoplasms, Carcinoma, Liver Neoplasms, Neoplasms, Neoplasms by Site, Digestive System Diseases, Adenocarcinoma, Neoplasms, Glandular and Epithelial
- Interventions
- ABT-869, Sorafenib
- Drug
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,035 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 13
- States / cities
- Beverly Hills, California • LaVerne, California • Orange, California + 8 more
- Conditions
- Neoplasm Metastases, Hepatic Insufficiency
- Interventions
- Trabectedin, Dexamethasone
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 6
- States / cities
- Scottsdale, Arizona • Detroit, Michigan • New York, New York + 3 more
- Conditions
- Multiple Myeloma, Diffuse Large B-Cell Lymphoma, Glioblastoma Multiforme, Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, Neuroendocrine Tumors of Non-Pancreatic Origin, Hormone Receptor-Positive Breast Cancer
- Interventions
- CC-223
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 226 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 10
- States / cities
- Los Angeles, California • San Francisco, California • Tampa, Florida + 6 more
- Conditions
- Liver Cancer
- Interventions
- alvocidib, irinotecan hydrochloride
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Castration-resistant Prostate Cancer, Non-small Cell Lung Cancer, Colorectal Cancer
- Interventions
- SM08502, Abiraterone, Prednisone, Docetaxel, FOLFIRI Protocol, Panitumumab
- Drug
- Lead sponsor
- Biosplice Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 16
- States / cities
- Tucson, Arizona • Aurora, Colorado • Scarborough, Maine + 11 more
- Conditions
- Cancer, Melanoma, Solid Tumor, Squamous Cell Carcinoma of Head and Neck, Breast Cancer, Advanced Solid Tumor, Triple Negative Breast Cancer, Colorectal Carcinoma, Non-melanoma Skin Cancer, Liver Metastases
- Interventions
- ONCR-177, pembrolizumab
- Biological
- Lead sponsor
- Oncorus, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 10
- States / cities
- Duarte, California • Denver, Colorado • Tampa, Florida + 6 more
- Conditions
- Neoplasms, Prostate Cancer, Lung Cancer, Breast Cancer, Colon Cancer
- Interventions
- ETBX-051; adenoviral brachyury vaccine, ETBX-061; adenoviral Mucin-1 (MUC1) vaccine, ETBX-011; adenoviral Carcinoembryonic antigen (CEA) vaccine
- Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Advanced Colorectal Cancer, Metastatic Colorectal Cancer
- Interventions
- MRTX849, Cetuximab, mFOLFOX6 Regimen, FOLFIRI Regimen
- Drug · Biological
- Lead sponsor
- Mirati Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 461 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 185
- States / cities
- Alabaster, Alabama • Bessemer, Alabama • Birmingham, Alabama + 122 more
- Conditions
- Colorectal Neoplasm
- Interventions
- DS-8201a
- Drug
- Lead sponsor
- Daiichi Sankyo Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 9
- States / cities
- Duarte, California • Los Angeles, California • Santa Monica, California + 6 more
- Conditions
- Colorectal Cancer
- Interventions
- gefitinib
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2003
- U.S. locations
- 2
- States / cities
- San Antonio, Texas
- Conditions
- Pancreatic Cancer
- Interventions
- gemcitabine hydrochloride, tacedinaline
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2001
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Tampa, Florida • Baltimore, Maryland + 8 more
- Conditions
- Biliary Tract Cancer, Biliary Tract Neoplasms
- Interventions
- Nivolumab
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 3
- States / cities
- Duarte, California • Tampa, Florida • Atlanta, Georgia
- Conditions
- Solid Tumors, Triple-Negative Breast Cancer, Non Small Cell Lung Cancer, Renal Cell Carcinoma, Mesothelioma, Fumarate Hydratase (FH)-Deficient Tumors, Succinate Dehydrogenase (SDH)-Deficient Gastrointestinal Stromal Tumors (GIST), Succinate Dehydrogenase (SDH)-Deficient Non-gastrointestinal Stromal Tumors, Tumors Harboring Isocitrate Dehydrogenase-1 (IDH1) and IDH2 Mutations, Tumors Harboring Amplifications in the cMyc Gene
- Interventions
- CB-839, Pac-CB, CBE, CB-Erl, CBD, CB-Cabo
- Drug
- Lead sponsor
- Calithera Biosciences, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 13
- States / cities
- San Francisco, California • Stanford, California • Sarasota, Florida + 7 more
- Conditions
- Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v7, Stage IIIC Hepatocellular Carcinoma AJCC v7, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8
- Interventions
- Nivolumab, Sorafenib
- Biological · Drug
- Lead sponsor
- Robin Kate Kelley
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 2
- States / cities
- Sacramento, California • San Francisco, California
- Conditions
- Extrahepatic Bile Duct Adenocarcinoma, Biliary Type, Gallbladder Adenocarcinoma, Biliary Type, Metastatic Pancreatic Adenocarcinoma, Recurrent Cholangiocarcinoma, Recurrent Gallbladder Carcinoma, Recurrent Hepatocellular Carcinoma, Recurrent Intrahepatic Cholangiocarcinoma, Recurrent Pancreatic Carcinoma, Stage III Gallbladder Cancer AJCC V7, Stage III Hepatocellular Carcinoma AJCC v7, Stage III Intrahepatic Cholangiocarcinoma AJCC v7, Stage III Pancreatic Cancer AJCC v6 and v7, Stage IIIA Gallbladder Cancer AJCC v7, Stage IIIA Hepatocellular Carcinoma AJCC v7, Stage IIIB Gallbladder Cancer AJCC v7, Stage IIIB Hepatocellular Carcinoma AJCC v7, Stage IIIC Hepatocellular Carcinoma AJCC v7, Stage IV Gallbladder Cancer AJCC v7, Stage IV Hepatocellular Carcinoma AJCC v7, Stage IV Pancreatic Cancer AJCC v6 and v7, Stage IVA Gallbladder Cancer AJCC v7, Stage IVA Hepatocellular Carcinoma AJCC v7, Stage IVA Intrahepatic Cholangiocarcinoma AJCC v7, Stage IVB Gallbladder Cancer AJCC v7, Stage IVB Hepatocellular Carcinoma AJCC v7, Stage IVB Intrahepatic Cholangiocarcinoma AJCC v7, Unresectable Gallbladder Carcinoma, Unresectable Pancreatic Carcinoma
- Interventions
- Durvalumab, Guadecitabine
- Biological · Drug
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Newport Beach, California • Baltimore, Maryland
- Conditions
- Metastatic Pancreatic Cancer
- Interventions
- ACP-196, ACP-196 in combination with pembrolizumab
- Drug
- Lead sponsor
- Acerta Pharma BV
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Esophageal Cancer, Gastric Cancer
- Interventions
- Afatinib and Paclitaxel
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2023
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Boston, Massachusetts • Basking Ridge, New Jersey + 6 more